Dr. Jorge M. Chaves, M.D.
Hematology & Oncology (Hematology & Oncology Physician)
1624 South I Street, Suite 102
Tacoma, WA 98405
Who else practices at this address →
Pierce County includes primary care (20% of residents) and dental (11% of residents) and mental health (11% of residents) shortage areas. About shortage areas
- Medicare participating
At a glance
- Medical school
- University of Texas Medical School at Houston (2005)
- Years since graduation
- 21
- In the NPI registry since
- 2008
- Medicare patients seen, 2024
- 628
Licensed in Washington since 2011, according to the Washington State Department of Health. We show license dates only for the states that publish them in bulk; see which states do. For other states, check the state medical board.
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2005Medical school: University of Texas Medical School at Houston
- 2008Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Hematology & Oncology Physician primary
WA license MD60199121 (first issued 2011; active)
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Tacoma General Allenmore Hospital Tacoma, WA
- St Joseph Medical Center Tacoma, WA
- St Michael Medical Center Silverdale, WA
- St Anthony Hospital Gig Harbor, WA
- St Clare Hospital Lakewood, WA
Medical groups
- Northwest Medical Specialties PLLC (38 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 628
- Services billed
- 135,302
- Patients’ average age
- 75
| Service | Times | Patients |
|---|---|---|
| Injection, filgrastim-aafi, biosimilar, (nivestym), 1 microgram | 16,620 | 13 |
| Injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (non-esrd use) | 14,790 | 26 |
| Injection, fosaprepitant, 1 mg | 12,000 | 37 |
| Injection, pembrolizumab, 1 mg | 7,800 | 14 |
| Injection, denosumab, 1 mg | 2,280 | 17 |
| Insertion of needle into vein for collection of blood sample | 1,524 | 389 |
| Injection, dexamethasone sodium phosphate, 1 mg | 1,504 | 75 |
| Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | 1,491 | 357 |
| Blood test, comprehensive group of blood chemicals | 1,392 | 380 |
| Flow cytometry technique for dna or cell analysis, each additional marker | 1,147 | 27 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Oxycodone Hcl Other prescribers in Tacoma, WA | 73 |
| Xarelto (rivaroxaban) Other prescribers in Tacoma, WA | 65 |
| Omeprazole Other prescribers in Tacoma, WA | 46 |
| Gabapentin Other prescribers in Tacoma, WA | 41 |
| Prednisone Other prescribers in Tacoma, WA | 39 |
| Levothyroxine Sodium Other prescribers in Tacoma, WA | 33 |
| Hydroxyurea Other prescribers in Tacoma, WA | 32 |
| Eliquis (apixaban) Other prescribers in Tacoma, WA | 31 |
| Megestrol Acetate Other prescribers in Tacoma, WA | 29 |
| Sulfamethoxazole-Trimethoprim (sulfamethoxazole/trimethoprim) Other prescribers in Tacoma, WA | 29 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 25 companies reported 56 payments worth $1,316 in total to this clinician.
| AbbVie Inc. | $187 |
|---|---|
| Janssen Biotech, Inc. | $135 |
| Incyte Corporation | $117 |
| Taiho Oncology, Inc. | $109 |
| Daiichi Sankyo Inc. | $68.11 |
| Regeneron Healthcare Solutions, Inc. | $52.82 |
| Astellas Pharma US Inc | $51.67 |
| Merck Sharp & Dohme LLC | $50.95 |
| Food and Beverage | $1,199 |
|---|---|
| Education | $116 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| AbbVie Inc. Nov 5, 2025 | Education IMBRUVICA · ONCOLOGY · in-kind | $99.99 |
| E.r. Squibb & Sons, L.l.c. Dec 10, 2025 | Education OPDIVO · Oncology · in-kind | $16.28 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 16 industry-funded studies in 2025, from 7 companies. The companies reported $592,815 in research payments for these studies, mostly to the institutions running them.
- A Study to Assess Adverse Events of Intravenously (IV) Infused Etentamig (ABBV-383) in Adult Participants With Relapsed or Refractory Multiple Myeloma
AbbVie Inc. · Recruiting · NCT05650632 - A Phase 1b, Protocol Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of Sotorasib Monotherapy and in Combination With Other Anti-cancer Therapies in Subjects With Advanced Solid Tumors With KRAS p.…
Amgen Inc. - U3-1402 in Metastatic or Unresectable Non-Small Cell Lung Cancer
Daiichi Sankyo Inc. · Active, not recruiting · NCT03260491 - A Study to Investigate Tislelizumab Administered as Subcutaneous Injection Versus Intravenous Infusion Plus Chemotherapy in Patients With Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma
Beone Medicines Ltd. · Recruiting · NCT07043400 - A Study to Determine Dose, Safety, Tolerability and Efficacy of CC-220 Monotherapy, and in Combination With Other Treatments in Subjects With Multiple Myeloma
Celgene Corporation · Active, not recruiting · NCT02773030 - Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 as Monotherapy and in Combination With IV Bevacizumab
AbbVie Inc. · Active, not recruiting · NCT05029882 - A Phase Ib Multicenter, Open-label Dose-escalation Study to Evaluate the Safety and Tolerability of Trastuzumab Deruxtecan (T-DXd) and Durvalumab in Combination with Cisplatin, Carboplatin or Pemetrexed in First-line …
AstraZeneca Pharmaceuticals LP - M24-536 - A Study to Evaluate the Adverse Events, Efficacy, and Optimal Dose of Intravenous (IV) Telisotuzumab Adizutecan in Combination With IV Budigalimab in Adult Participants With Advanced or Metastatic Non-Squamo…
AbbVie Inc. - A Phase 1b Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of AMG 193 Alone or in Combination With Other Therapies in Subjects With Advanced Thoracic Tumors With Homozygous MTAP-deletion (Mas…
Amgen Inc. - A Phase 1b Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of AMG 193 in Combination With Other Therapies in Subjects With Advanced Gastrointestinal, Biliary Tract, or Pancreatic Cancers With…
Amgen Inc.
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.